title: Dapsone-pyrimethamine compared with aerosolized pentamidine as primary prophylaxis against Pneumocystis carinii pneumonia and toxoplasmosis in HIV infection. The PRIO Study Group.
abstract: BACKGROUND
  Pneumocystis carinii pneumonia and toxoplasmic encephalitis are frequent life-threatening opportunistic infections in patients with human immunodeficiency virus (HIV) infection. Primary prophylaxis against P. carinii pneumonia is now common, but there are few data on regimens for primary prophylaxis against toxoplasmosis.
  
  
  METHODS
  We conducted a randomized trial that compared two prophylactic regimens: dapsone (50 mg per day) plus pyrimethamine (50 mg per week) was compared with aerosolized pentamidine (300 mg per month). The patients had symptomatic HIV infection, no history of P. carinii pneumonia or symptomatic toxoplasmosis, and CD4+ counts below 200 per cubic millimeter (0.2 x 10(9) per liter).
  
  
  RESULTS
  In an intention-to-treat analysis, after a median follow-up of 539 days P. carinii pneumonia developed in 10 patients in each group, whereas toxoplasmosis developed in 32 of 176 patients in the pentamidine group and 19 of 173 patients in the dapsone-pyrimethamine group. Those assigned to pentamidine had a risk of P. carinii pneumonia that was similar to the risk in those assigned to dapsone-pyrimethamine (adjusted relative risk, 1.13; 95 percent confidence interval, 0.44 to 2.92; P = 0.79), but a higher risk of toxoplasmosis (adjusted relative risk, 1.81; 95 percent confidence interval, 1.12 to 2.94; P = 0.02). Among the 262 patients with serologic evidence of past exposure to Toxoplasma gondii, the relative risk of symptomatic toxoplasmosis was 2.37 times higher in those assigned to pentamidine (95 percent confidence interval, 1.3 to 4.4; P = 0.006). More patients discontinued dapsone-pyrimethamine than pentamidine because of toxicity (42 vs. 3; P < 0.001). Survival was similar in the two groups.
  
  
  CONCLUSIONS
  For primary prevention of P. carinii pneumonia, dapsone-pyrimethamine is as effective, though not as well tolerated, as aerosolized pentamidine. Dapsone-pyrimethamine also prevents first episodes of toxoplasmosis.
authors: Institut National de la Santé et de la Recherche Médicale, Unité 13, Paris, France.
authors: P M
authors: PM
authors: Girard
authors: R
authors: R
authors: Landman
authors: C
authors: C
authors: Gaudebout
authors: R
authors: R
authors: Olivares
authors: A G
authors: AG
authors: Saimot
authors: P
authors: P
authors: Jelazko
authors: C
authors: C
authors: Gaudebout
authors: A
authors: A
authors: Certain
authors: F
authors: F
authors: Boué
authors: E
authors: E
authors: Bouvet
mesh_terms: D000386:AIDS-Related Complex / Q000150:complications / Q000188:drug therapy; D017088:AIDS-Related Opportunistic Infections / Q000401:mortality / Q000517:prevention & control*; D000328:Adult; D003622:Dapsone / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use; D004338:Drug Combinations; D004660:Encephalitis / Q000401:mortality / Q000517:prevention & control*; D005260:Female; D015658:HIV Infections / Q000150:complications / Q000188:drug therapy; D006801:Humans; D008297:Male; D010419:Pentamidine / Q000008:administration & dosage* / Q000627:therapeutic use; D011020:Pneumonia, Pneumocystis / Q000401:mortality / Q000517:prevention & control*; D011739:Pyrimethamine / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use; D016781:Toxoplasmosis, Cerebral / Q000401:mortality / Q000517:prevention & control*; D015215:Zidovudine / Q000627:therapeutic use
chemical_list: D004338:Drug Combinations; D015215:Zidovudine; D010419:Pentamidine; D003622:Dapsone; D011739:Pyrimethamine